Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATFurniture, Fixtures and OtherLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShort-Term Debt repayments
Ratios

Plus Therapeutics (PSTV) EBIAT (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed EBIAT for 15 consecutive years, with -$5.7 million as the latest value for Q4 2025.

  • Quarterly EBIAT fell 46.04% to -$5.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$22.4 million through Dec 2025, down 72.39% year-over-year, with the annual reading at -$22.4 million for FY2025, 72.6% down from the prior year.
  • EBIAT for Q4 2025 was -$5.7 million at Plus Therapeutics, down from -$4.4 million in the prior quarter.
  • The five-year high for EBIAT was $5.2 million in Q2 2025, with the low at -$17.4 million in Q1 2025.
  • Average EBIAT over 5 years is -$4.1 million, with a median of -$3.8 million recorded in 2023.
  • Peak annual rise in EBIAT hit 275.2% in 2025, while the deepest fall reached 433.61% in 2025.
  • Over 5 years, EBIAT stood at -$3.7 million in 2021, then crashed by 51.93% to -$5.7 million in 2022, then skyrocketed by 32.66% to -$3.8 million in 2023, then decreased by 2.44% to -$3.9 million in 2024, then crashed by 46.04% to -$5.7 million in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at -$5.7 million, -$4.4 million, and $5.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.